Literature DB >> 30355580

Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow.

Céline Mazzotti1, Laure Buisson1, Sabrina Maheo1, Aurore Perrot2, Marie-Lorraine Chretien3, Xavier Leleu4, Cyrille Hulin5, Salomon Manier6, Benjamin Hébraud1, Murielle Roussel1, Laura Do Souto1, Michel Attal1, Hervé Avet-Loiseau1, Jill Corre1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30355580      PMCID： PMC6234381          DOI： 10.1182/bloodadvances.2018025197

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  17 in total

1.  Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

Authors:  Mark Roschewski; Kieron Dunleavy; Stefania Pittaluga; Martin Moorhead; Francois Pepin; Katherine Kong; Margaret Shovlin; Elaine S Jaffe; Louis M Staudt; Catherine Lai; Seth M Steinberg; Clara C Chen; Jianbiao Zheng; Thomas D Willis; Malek Faham; Wyndham H Wilson
Journal:  Lancet Oncol       Date:  2015-04-01       Impact factor: 41.316

2.  Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authors:  Paul G Richardson; Edie Weller; Sagar Lonial; Andrzej J Jakubowiak; Sundar Jagannath; Noopur S Raje; David E Avigan; Wanling Xie; Irene M Ghobrial; Robert L Schlossman; Amitabha Mazumder; Nikhil C Munshi; David H Vesole; Robin Joyce; Jonathan L Kaufman; Deborah Doss; Diane L Warren; Laura E Lunde; Sarah Kaster; Carol Delaney; Teru Hideshima; Constantine S Mitsiades; Robert Knight; Dixie-Lee Esseltine; Kenneth C Anderson
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

3.  Circulating cell-free DNA in hematological malignancies.

Authors:  Lieselot Buedts; Peter Vandenberghe
Journal:  Haematologica       Date:  2016-09       Impact factor: 9.941

4.  Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma.

Authors:  S Mithraprabhu; T Khong; M Ramachandran; A Chow; D Klarica; L Mai; S Walsh; D Broemeling; A Marziali; M Wiggin; J Hocking; A Kalff; B Durie; A Spencer
Journal:  Leukemia       Date:  2016-11-30       Impact factor: 11.528

Review 5.  Liquid biopsies come of age: towards implementation of circulating tumour DNA.

Authors:  Jonathan C M Wan; Charles Massie; Javier Garcia-Corbacho; Florent Mouliere; James D Brenton; Carlos Caldas; Simon Pacey; Richard Baird; Nitzan Rosenfeld
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

6.  Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer.

Authors:  Jeanne Tie; Yuxuan Wang; Cristian Tomasetti; Lu Li; Simeon Springer; Isaac Kinde; Natalie Silliman; Mark Tacey; Hui-Li Wong; Michael Christie; Suzanne Kosmider; Iain Skinner; Rachel Wong; Malcolm Steel; Ben Tran; Jayesh Desai; Ian Jones; Andrew Haydon; Theresa Hayes; Tim J Price; Robert L Strausberg; Luis A Diaz; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Peter Gibbs
Journal:  Sci Transl Med       Date:  2016-07-06       Impact factor: 17.956

7.  Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Authors:  Guangwu Guo; Noopur S Raje; Charles Seifer; Jake Kloeber; Randi Isenhart; Gavin Ha; Andrew J Yee; Elizabeth K O'Donnell; Yu-Tzu Tai; Paul G Richardson; Giada Bianchi; Jacob P Laubach; Diane Warren; Erica Gemme; Jordan Voisine; Julia Frede; Antonis Kokkalis; Huiyoung Yun; Valeriya Dimitrova; Tushara Vijaykumar; Matthew Meyerson; Nikhil C Munshi; Kenneth C Anderson; Birgit Knoechel; Jens G Lohr
Journal:  Leukemia       Date:  2018-03-27       Impact factor: 11.528

8.  Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA.

Authors:  Anna Oberle; Anna Brandt; Minna Voigtlaender; Benjamin Thiele; Janina Radloff; Anita Schulenkorf; Malik Alawi; Nuray Akyüz; Manuela März; Christopher T Ford; Artus Krohn-Grimberghe; Mascha Binder
Journal:  Haematologica       Date:  2017-02-09       Impact factor: 9.941

9.  Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.

Authors:  Olena Kis; Rayan Kaedbey; Signy Chow; Arnavaz Danesh; Mark Dowar; Tiantian Li; Zhihua Li; Jessica Liu; Mark Mansour; Esther Masih-Khan; Tong Zhang; Scott V Bratman; Amit M Oza; Suzanne Kamel-Reid; Suzanne Trudel; Trevor J Pugh
Journal:  Nat Commun       Date:  2017-05-11       Impact factor: 14.919

10.  Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Authors:  Aurore Perrot; Valerie Lauwers-Cances; Jill Corre; Nelly Robillard; Cyrille Hulin; Marie-Lorraine Chretien; Thomas Dejoie; Sabrina Maheo; Anne-Marie Stoppa; Brigitte Pegourie; Lionel Karlin; Laurent Garderet; Bertrand Arnulf; Chantal Doyen; Nathalie Meuleman; Bruno Royer; Jean-Richard Eveillard; Lotfi Benboubker; Mamoun Dib; Olivier Decaux; Arnaud Jaccard; Karim Belhadj; Sabine Brechignac; Brigitte Kolb; Cecile Fohrer; Mohamad Mohty; Margaret Macro; Paul G Richardson; Victoria Carlton; Martin Moorhead; Tom Willis; Malek Faham; Kenneth C Anderson; Jean-Luc Harousseau; Xavier Leleu; Thierry Facon; Philippe Moreau; Michel Attal; Hervé Avet-Loiseau; Nikhil Munshi
Journal:  Blood       Date:  2018-09-24       Impact factor: 25.476
View more
  27 in total

Review 1.  Tracking myeloma tumor DNA in peripheral blood.

Authors:  Johannes M Waldschmidt; Tushara Vijaykumar; Birgit Knoechel; Jens G Lohr
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-14       Impact factor: 3.020

Review 2.  Determination of Minimal Residual Disease in Multiple Myeloma: Does It Matter?

Authors:  Shalin Kothari; Jens Hillengass; Philip L McCarthy; Sarah A Holstein
Journal:  Curr Hematol Malig Rep       Date:  2019-02       Impact factor: 3.952

3.  Comparison of MALDI-TOF mass spectrometry analysis of peripheral blood and bone marrow-based flow cytometry for tracking measurable residual disease in patients with multiple myeloma.

Authors:  Marion Eveillard; Even Rustad; Mikhail Roshal; Yanming Zhang; Amanda Ciardiello; Neha Korde; Malin Hultcrantz; Sydney Lu; Urvi Shah; Hani Hassoun; Eric Smith; Alexander Lesokhin; Sham Mailankody; Ola Landgren; Katie Thoren
Journal:  Br J Haematol       Date:  2020-02-05       Impact factor: 6.998

4.  Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.

Authors:  Luzalba Sanoja-Flores; Juan Flores-Montero; Noemi Puig; Teresa Contreras-Sanfeliciano; Roberia Pontes; Alba Corral-Mateos; Omar García-Sánchez; María Díez-Campelo; Roberto José Pessoa de Magalhães; Luis García-Martín; José María Alonso-Alonso; Aranzazú García-Mateo; Carlos Aguilar-Franco; Jorge Labrador; Abelardo Barez-García; Angelo Maiolino; Bruno Paiva; Jesús San Miguel; Elaine Sobral da Costa; Marcos González; María Victoria Mateos; Brian Durie; Jacques J M van Dongen; Alberto Orfao
Journal:  Blood       Date:  2019-12-12       Impact factor: 22.113

5.  Minimal residual disease in multiple myeloma: why, when, where.

Authors:  Andrew J Yee; Noopur Raje
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.

Authors:  Malin Hultcrantz; Even H Rustad; Venkata Yellapantula; Allison Jacob; Theresia Akhlaghi; Neha Korde; Sham Mailankody; Alexander M Lesokhin; Hani Hassoun; Eric L Smith; Oscar B Lahoud; Heather J Landau; Gunjan L Shah; Michael Scordo; David J Chung; Sergio Giralt; Elli Papaemmanuil; Ola Landgren
Journal:  Clin Cancer Res       Date:  2022-05-13       Impact factor: 13.801

Review 7.  Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.

Authors:  Sridurga Mithraprabhu; Maoshan Chen; Ioanna Savvidou; Antonia Reale; Andrew Spencer
Journal:  Leukemia       Date:  2021-07-14       Impact factor: 11.528

Review 8.  Role of Circulating Tumor DNA in Hematological Malignancy.

Authors:  Miho Ogawa; Kazuaki Yokoyama; Seiya Imoto; Arinobu Tojo
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 9.  Measurable residual disease in multiple myeloma: ready for clinical practice?

Authors:  Leire Burgos; Noemi Puig; Maria-Teresa Cedena; María-Victoria Mateos; Juan José Lahuerta; Bruno Paiva; Jesús F San-Miguel
Journal:  J Hematol Oncol       Date:  2020-06-22       Impact factor: 17.388

Review 10.  International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.

Authors:  Luciano J Costa; Benjamin A Derman; Susan Bal; Surbhi Sidana; Saurabh Chhabra; Rebecca Silbermann; Jing C Ye; Gordon Cook; Robert F Cornell; Sarah A Holstein; Qian Shi; James Omel; Natalie S Callander; Wee Joo Chng; Vania Hungria; Angelo Maiolino; Edward Stadtmauer; Sergio Giralt; Marcelo Pasquini; Andrzej J Jakubowiak; Gareth J Morgan; Amrita Krishnan; Graham H Jackson; Mohamad Mohty; Maria Victoria Mateos; Meletious A Dimopoulos; Thierry Facon; Andrew Spencer; Jesus San Miguel; Parameswaran Hari; Saad Z Usmani; Salomon Manier; Phillip McCarthy; Shaji Kumar; Francesca Gay; Bruno Paiva
Journal:  Leukemia       Date:  2020-08-11       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.